TY - JOUR
TI - Erratum: A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: Analysis of parameters that improve outcome (Haematologica (2020) 10:51 (201-208) DOI: 10.3324/haematol.2019.219295)
AU - Beksac, M.
AU - Seval, G.C.
AU - Kanellias, N.
AU - Coriu, D.
AU - Rosiñol, L.
AU - Ozet, G.
AU - Goranova-Marinova, V.
AU - Unal, A.
AU - Bila, J.
AU - Ozsan, H.
AU - Ivanaj, A.
AU - Balić, L.I.
AU - Kastritis, E.
AU - Bladé, J.
AU - Dimopoulos, M.A.
JO - Haematologica-the hematology journal
PY - 2021
VL - 106
TODO - 4
SP - 1228
PB - Ferrata Storti Foundation
SN - null
TODO - 10.3324/haematol.2020.278272
TODO - erratum
TODO - We have noticed an error in the progression-free survival of patients with extramedullary plasmacytoma in our article published in Haematologica in January 2020 (doi: HAEMATOL/2019/219295). The following sentence in the abstract: “Extramedullary plasmacytoma at relapse had the worst prognosis with a PFS of 13.6 months and overall survival of 11.4 months.” Should be replaced by: “Extramedullary plasmacytoma at relapse had the worst prognosis with a PFS of 9.1 months and overall survival of 11.4 months.” Likewise, on page 205, the following sentence: “However, if diagnosed at relapse, PFS and OS were 13.6 months and 11.4 months for EMP compared to 20.9 months (P=0.249) and 39.8 months (P=0.093) for PO, respectively (Table 2 and Figure 1).” Should be replaced by: “However, if diagnosed at relapse, PFS and OS were 9.1 months and 11.4 months for EMP compared to 20.9 months (P=0.249) and 39.8 months (P=0.093) for PO, respectively (Table 2 and Figure 1).” The error was also present in Table 2. The corrected Table 2 is shown below. © 2021 Ferrata Storti Foundation
ER -